Bank of New York Mellon
MRSN

Bank of New York Mellon’s Mersana Therapeutics MRSN Stock Holding History

Bank of New York Mellon’s Portfolio MRSN Stock Details MRSN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-2,663
Closed -$19.7K – 4230
2025
Q2 		$19.7K Sell
2,663
-11,185
-81% -$98.3K ﹤0.01% 4113
2025
Q1 		$119K Hold
13,848
– – ﹤0.01% 3981
2024
Q4 		$495K Sell
13,848
-1,039
-7% -$53.7K ﹤0.01% 3534
2024
Q3 		$703K Sell
14,887
-3,226
-18% -$142K ﹤0.01% 3330
2024
Q2 		$910K Buy
18,113
+2,964
+20% +$214K ﹤0.01% 3259
2024
Q1 		$1.7M Sell
15,149
-317
-2% -$31.5K ﹤0.01% 2854
2023
Q4 		$897K Buy
15,466
+436
+3% +$17.5K ﹤0.01% 3244
2023
Q3 		$477K Sell
15,030
-37
-0.2% -$1.76K ﹤0.01% 3570
2023
Q2 		$1.24M Buy
15,067
+276
+2% +$40.4K ﹤0.01% 3081
2023
Q1 		$1.52M Buy
14,791
+70
+0.5% +$9.82K ﹤0.01% 2945
2022
Q4 		$2.16M Buy
14,721
+297
+2% +$50.2K ﹤0.01% 2822
2022
Q3 		$2.44M Buy
14,424
+676
+5% +$110K ﹤0.01% 2716
2022
Q2 		$1.59M Buy
13,748
+2,424
+21% +$228K ﹤0.01% 2960
2022
Q1 		$1.13M Buy
11,324
+127
+1% +$14.8K ﹤0.01% 3236
2021
Q4 		$1.74M Buy
11,197
+365
+3% +$71K ﹤0.01% 3075
2021
Q3 		$2.55M Buy
10,832
+872
+9% +$255K ﹤0.01% 2848
2021
Q2 		$3.38M Sell
9,960
-500
-5% -$189K ﹤0.01% 2680
2021
Q1 		$4.23M Sell
10,460
-599
-5% -$291K ﹤0.01% 2517
2020
Q4 		$7.36M Sell
11,059
-76
-0.7% -$42.3K ﹤0.01% 2165
2020
Q3 		$5.18M Buy
11,135
+281
+3% +$142K ﹤0.01% 2199
2020
Q2 		$6.35M Buy
10,854
+3,053
+39% +$1.04M ﹤0.01% 2090
2020
Q1 		$1.14M Buy
7,801
+31
+0.4% +$5.42K ﹤0.01% 2883
2019
Q4 		$1.11M Buy
7,770
+3,726
+92% +$272K ﹤0.01% 3187
2019
Q3 		$160K Sell
4,044
-244
-6% -$17.7K ﹤0.01% 3945
2019
Q2 		$434K Buy
4,288
+2,738
+177% +$323K ﹤0.01% 3670
2019
Q1 		$204K Sell
1,550
-18
-1% -$2.27K ﹤0.01% 3883
2018
Q4 		$160K Buy
1,568
+252
+19% +$39.9K ﹤0.01% 3892
2018
Q3 		$329K Buy
1,316
+51
+4% +$17.1K ﹤0.01% 3795
2018
Q2 		$564K Buy
1,265
+273
+28% +$120K ﹤0.01% 3579
2018
Q1 		$392K Buy
992
+375
+61% +$148K ﹤0.01% 3690
2017
Q4 		$254K Buy
617
+83
+16% +$36.2K ﹤0.01% 3864
2017
Q3 		$231K Buy
+534
New +$210K ﹤0.01% 3829

Other funds holding MRSN

NI
Nextech Invest Zurich, Switzerland $1.42B AUM 304.47% 1-Year Est. Return
AV
Alamea Verwaltungs Edison, New Jersey $135M AUM 36.32% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SSA
Schonfeld Strategic Advisors New York $14.2B AUM 37.17% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
SCM
Silverarc Capital Management Boston, Massachusetts $980M AUM 470.8% 1-Year Est. Return
6CM
683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Bank of New York Mellon's MRSN Position: Q3 2025 in Review

Bank of New York Mellon sold out of Mersana Therapeutics (MRSN) in Q3 2025, closing a stake of 2,663 shares — an estimated $19.7K sold.

Bank of New York Mellon first reported a position in MRSN in Q3 2017 and held it in 32 quarters. The position peaked at $7.36M in Q4 2020. 49 funds tracked by Wall St. Rank hold MRSN as of Q3 2025.

  • Bank of New York Mellon reported no remaining Mersana Therapeutics position as of Q3 2025 after selling out during the quarter.
  • Bank of New York Mellon sold 2,663 Mersana Therapeutics shares in Q3 2025, an estimated $19.7K.
  • Bank of New York Mellon first reported a position in Mersana Therapeutics in Q3 2017 and held it in 32 quarters.
  • Bank of New York Mellon's Mersana Therapeutics position peaked at $7.36M in Q4 2020.
  • 49 funds tracked by Wall St. Rank held Mersana Therapeutics as of Q3 2025.

Based on Bank of New York Mellon's 13F filing for Q3 2025, filed 3 Nov 2025.